| First Author | Jin G | Year | 2024 |
| Journal | Nat Immunol | Volume | 25 |
| Issue | 6 | Pages | 1059-1072 |
| PubMed ID | 38802511 | Mgi Jnum | J:362426 |
| Mgi Id | MGI:7859393 | Doi | 10.1038/s41590-024-01834-9 |
| Citation | Jin G, et al. (2024) A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice. Nat Immunol 25(6):1059-1072 |
| abstractText | Asthma, the most prevalent respiratory disease, affects more than 300 million people and causes more than 250,000 deaths annually. Type 2-high asthma is characterized by interleukin (IL)-5-driven eosinophilia, along with airway inflammation and remodeling caused by IL-4 and IL-13. Here we utilize IL-5 as the targeting domain and deplete BCOR and ZC3H12A to engineer long-lived chimeric antigen receptor (CAR) T cells that can eradicate eosinophils. We call these cells immortal-like and functional IL-5 CAR T cells (5T(IF)) cells. 5T(IF) cells were further modified to secrete an IL-4 mutein that blocks IL-4 and IL-13 signaling, designated as 5T(IF)4 cells. In asthma models, a single infusion of 5T(IF)4 cells in fully immunocompetent mice, without any conditioning regimen, led to sustained repression of lung inflammation and alleviation of asthmatic symptoms. These data show that asthma, a common chronic disease, can be pushed into long-term remission with a single dose of long-lived CAR T cells. |
